Medtronic Earnings On Deck – What You Need To Know Into The Print

Medtronic reports fiscal Q3 2026 results on Tuesday, February 17 before market open, testing whether tariff headwinds will compress margins despite cardiovascular momentum. The quarter provides the first test of management’s tariff-impact framework, with the company guiding to an adjusted EPS midpoint of $1.33 and warning that Q3 will absorb roughly half of the full-year tariff burden.

Consensus sits at $8.89B revenue and $1.33 EPS, converging with management’s own guide after a year-long reset that saw Street expectations drop from $5.83 to $5.64 for fiscal 2026. The setup creates minimal room for upside surprise on the headline number, shifting the focus to whether cardiovascular acceleration and pulsed-field ablation momentum can offset the concentrated cost pressure.

The quarter matters less for whether Medtronic beats its own guide and more for whether management can protect confidence in the fiscal 2026 margin bridge. After raising full-year organic revenue growth to approximately 5.5% in November and lifting the adjusted EPS range to $5.62–$5.66, the company explicitly called out Q3 as the period of maximum tariff concentration, with roughly $90–$95M in tariff-related cost of goods sold impact.

WELCOME BONUS Trade Thousands Of Global Markets Demo account, mobile app and multi-platform access IG

5.0

Visit Site

Empfohlener Broker Multi Asset Platform

Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro

5.0

Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

Medtronic’s corporate headquarters features the iconic “Rising Man” sculpture, symbolizing the company’s mission to alleviate pain, restore health, and extend life.

Consensus Estimates

Consensus has converged with management’s Q3 adjusted EPS guide of $1.32–$1.34, eliminating the estimate gap that characterized much of fiscal 2026. The stability in revisions over the past 30 days reflects Street acceptance of the tariff-heavy quarter framework rather than confidence in upside potential. Revenue expectations of $8.89B represent 7.2% year-over-year growth, consistent with the company’s raised full-year organic growth outlook of approximately 5.5%.

The cardiovascular segment carries the highest growth expectation at 10.8%, driven by cardiac ablation solutions and the pulsed-field ablation platform that delivered 71% growth in the prior quarter. Neuroscience revenue is projected to grow 5.3%, with cranial and spinal technologies expected to contribute 6% growth and neuromodulation 6.2%.

Management Guidance and Commentary

“We expect Q3 to see roughly half of our annual tariff impact, with about $90 to $95 million in tariff-related cost of goods sold impact concentrated in this quarter.”

Management’s November 2025 prepared remarks explicitly framed Q3 as the period of maximum tariff burden, providing a clear setup for margin pressure. The $90–$95M tariff impact in Q3 implies a full-year tariff cost of approximately $185M, down from the initial $200–$350M range cited in May 2025. The reduction in the tariff assumption was the basis for the August 2025 guidance raise to $5.60–$5.66 adjusted EPS.

“Enterprise growth drivers are accelerating, with cardiac ablation solutions growing 71% and continued momentum across our innovation platforms.”

The Q2 commentary emphasized cardiovascular strength, particularly pulsed-field ablation adoption, as the primary offset to tariff headwinds. The 71% growth in cardiac ablation solutions represents a category-level acceleration that tends to raise confidence in sustainable organic growth, but the market will scrutinize whether that momentum continued into Q3.

Analyst Price Targets & Ratings

Wall Street maintains a constructive view with 80% of analysts rating shares a Buy or Strong Buy. The consensus target of $112.00 implies 12.6% upside from current levels, though this reflects expectations for successful navigation of the tariff headwinds and sustained innovation-led growth rather than near-term catalysts.

Sector & Peer Comparison

Medtronic trades at 17.6x forward earnings, a discount to Boston Scientific (28.1x), Stryker (24.3x), and Abbott (21.4x), but a premium to Becton Dickinson (14.9x) and Zimmer Biomet (12.7x). The valuation positioning reflects a company in transition: the Diabetes separation removes a lower-margin, slower-growth business, but execution risk around the spinoff and the tariff-heavy cost environment have kept the multiple compressed relative to faster-growing peers.

Earnings Track Record

Medtronic has delivered 17 beats in the last 18 quarters, a 94.4% beat rate with an average surprise of 2.5%. The consistency establishes credibility on earnings execution, but the pattern also reveals a critical dynamic: beats have not consistently translated into positive stock reactions. The most recent quarter (October 2025) posted a 3.8% EPS beat and revenue above consensus, yet the stock declined 0.8% the next day.

Post-Earnings Price Movement History

The average next-day move following earnings is -1.2%, with the stock declining after five of the last six beats. The pattern suggests investors consistently find something to dislike in the details, whether revenue quality, guidance tone, or segment mix, even when the headline EPS number exceeds expectations.

Expected Move & Implied Volatility

The options market is pricing a 3.5% expected move, modestly above the historical average but consistent with recent volatility around guidance-driven quarters. The 22% implied volatility sits at the 45th percentile of the past year’s range, suggesting the market sees elevated but not extreme uncertainty.

Expert Predictions & What to Watch

Key Outlook: Cautiously Neutral

Key Metrics to Watch

Cardiovascular revenue is the single most important metric. The segment’s 10.8% expected growth accounts for a disproportionate share of the company’s organic growth acceleration. Gross margin will reveal whether the tariff impact is tracking to the $90–$95M assumption or running higher. PFA growth is the litmus test for innovation credibility—any deceleration below 60% would raise questions about platform sustainability.